Clinical Trials
Sterna biologicals conducts clinical trials to advance its development pipeline. Our lead compound, SB010 for moderate and severe Th2-driven asthma, is currently being evaluated in a Phase IIa proof-of-concept trial. We expect SB011 for atopic dermatitis to start trials in 2012.
| Compound | Indication | Phase | Description | Status | Further Details |
|---|---|---|---|---|---|
| SB010 | Asthma |
I |
Single dose |
completed |
|
|
I |
Multiple dose |
completed |
|||
|
I |
Safety in asthmatics |
completed |
|||
|
IIa |
Proof-of-Concept |
ongoing |
We also report results of registered clinical trials to www.clinicaltrials.gov.